Suresh K. Rayala
YOU?
Author Swipe
View article: Supplementary Figure S13 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S13 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S13 shows the representative images (20X) and Q score quantification of immunohistochemistry analysis of PCNA in mouse mammary tumor sections
View article: Supplementary Table S1 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Table S1 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
SUPPLEMENTARY TABLE S1. IC50 Values of chemotherapeutic drugs in BT549, MDA MB 231 and 4T1 (WT & PAK1 KO)
View article: Supplementary Figure S5 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S5 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S5 shows representative microscopic images (10X) of wound healing assay in MDA MB 231 (0h & 24h)
View article: Supplementary Table S3 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Table S3 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
SUPPLEMENTARY TABLE S3. Combination Index (CI) values of Chemotherapeutic drugs and PAK1 inhibitors in BT549, MDA MB 231 and 4T1
View article: Supplementary Figure S2 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S2 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S2 shows the synergistic Fa-CI plots analyzed using Compusyn software for NVS PAK1 with drugs doxorubicin and paclitaxel in BT549, with doxorubicin, paclitaxel, docetaxel, methotrexate and epirubicin in MDA MB 231, and…
View article: Supplementary Figure S11 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S11 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S11 shows the representative images (20X) and Q score quantification of immunohistochemistry analysis of pPAK1 S144 in mouse mammary tumor sections
View article: Supplementary Figure S3 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S3 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S3 shows representative images of colony formation assay in BT549, MDA-MB-231 and 4T1
View article: Supplementary Figure S4 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S4 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S4 shows representative microscopic images (10X) of wound healing assay in BT549 (0h & 24h)
View article: Supplementary Figure S6 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S6 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S6 shows representative microscopic images (10X) of wound healing assay in 4T1 (0h & 24h)
View article: Supplementary Table S4 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Table S4 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
SUPPLEMENTARY TABLE S4. Combinational Effective Dose Values (ED50) of synergistic chemotherapeutic drugs with NVS PAK1 in BT549, MDA MB 231 and 4T1
View article: Supplementary Table S2 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Table S2 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
SUPPLEMENTARY TABLE S2. IC50 Values of PAK1 inhibitors in BT549, MDA MB 231 and 4T1
View article: Supplementary Figure S7 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S7 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S7 shows representative microscopic images (10X) of transwell migration assays in BT549, MDA-MB-231 and 4T1
View article: Supplementary Figure S14 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S14 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S14 shows the representative images (20X) and Q score quantification of immunohistochemistry analysis of Ki67 in mouse mammary tumor sections
View article: Supplementary Figure S9 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S9 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S9 shows the graphical representation of relative body weight of mice on treatment with Doxorubicin, Paclitaxel, Methotrexate and all in combination with NVS PAK1 to the initial weight of mice before the treatment
View article: Supplementary Figure S8 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S8 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S8 presents the scatter plots showing apoptosis in single and combinational drug treated MDA MB 231 cells, analyzed by flow cytometry, quantification of apoptotic cells was based on the four populations: Q1 (Live), Q2 …
View article: Supplementary Figure S1 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S1 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S1 shows single agent dose response curves for determination of IC50 values of chemotherapeutic drugs & PAK1 Inhibitors in two TNBC cell lines and in a mouse mammary tumor cell line 4T1, all the IC50 values are in µM u…
View article: Data from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Data from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Most of the triple-negative phenotypes or basal-like molecular subtypes of breast cancers are associated with aggressive clinical behavior and show poor disease prognosis. Current treatment options are constrained, emphasizing the need for…
View article: Supplementary Figure S12 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S12 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S12 shows the representative images (20X) and Q score quantification of immunohistochemistry analysis of PAK1 in mouse mammary tumor sections
View article: Supplementary Figure S10 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S10 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S10 shows the representative H&E images (20X) of dissected mouse mammary tumor sections
View article: Supplementary Figure S15 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer
Supplementary Figure S15 from Novel Combination Therapy Targeting Oncogenic Signaling Kinase P21-Activated Kinase 1 and Chemotherapeutic Drugs Against Triple-Negative Breast Cancer Open
Supplementary Figure S15 shows the representative H&E images (20X) of lung sections from control, single drug treated and combination drug treated mice group
View article: P21‐Activated Kinase 1 (PAK1) Modulates Therapeutic Response to Ionizing Radiation in Head and Neck Squamous Cell Carcinoma Cells
P21‐Activated Kinase 1 (PAK1) Modulates Therapeutic Response to Ionizing Radiation in Head and Neck Squamous Cell Carcinoma Cells Open
Head and neck squamous cell carcinoma (HNSCC) continues to be a formidable epithelial malignancy characterized by late‐stage detection and recurrence impacting survival. P21‐activated kinase‐1 (PAK1) was reported to be overexpressed in hea…
View article: Pak1 dysregulates pyruvate metabolism in PDAC cells by exerting a phosphorylation-mediated regulatory effect on PDHA1
Pak1 dysregulates pyruvate metabolism in PDAC cells by exerting a phosphorylation-mediated regulatory effect on PDHA1 Open
View article: Intelligent Smart Mirror with Voice Recognition and Home Automation
Intelligent Smart Mirror with Voice Recognition and Home Automation Open
The Project illustrates the design and development of a clever mirror that shows an exquisite interface for glimpsing data. Intelligent mirror, which continues the workings today, and will take its place in technology forthcoming, provides…
View article: Supplementary Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen
Supplementary Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen Open
Supplementary Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen
View article: Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen
Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen Open
Purpose: Tamoxifen is one of many standard therapeutic options currently available for estrogen receptor-α–positive breast cancer patients. Emerging data have suggested that levels of estrogen receptor coregulatory proteins play a s…
View article: Supplementary Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen
Supplementary Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen Open
Supplementary Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen
View article: Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen
Data from Extranuclear Coactivator Signaling Confers Insensitivity to Tamoxifen Open
Purpose: Tamoxifen is one of many standard therapeutic options currently available for estrogen receptor-α–positive breast cancer patients. Emerging data have suggested that levels of estrogen receptor coregulatory proteins play a s…
View article: Supplementary Table 1 from MTA1 Promotes STAT3 Transcription and Pulmonary Metastasis in Breast Cancer
Supplementary Table 1 from MTA1 Promotes STAT3 Transcription and Pulmonary Metastasis in Breast Cancer Open
PDF file - 21K, Primers used in RT-PCR and qPCR; Primers used for ChIP on mouse Stat3 promoter; Primers used of ChIP on mouse Twist1 promoter.
View article: Supplementary Figures 1-5 from Metastasis-Associated Protein 1 and Its Short Form Variant Stimulates <i>Wnt1</i> Transcription through Promoting Its Derepression from <i>Six3</i> Corepressor
Supplementary Figures 1-5 from Metastasis-Associated Protein 1 and Its Short Form Variant Stimulates <i>Wnt1</i> Transcription through Promoting Its Derepression from <i>Six3</i> Corepressor Open
Supplementary Figures 1-5 from Metastasis-Associated Protein 1 and Its Short Form Variant Stimulates Wnt1 Transcription through Promoting Its Derepression from Six3 Corepressor
View article: Data from Metastasis-Associated Protein 1 and Its Short Form Variant Stimulates <i>Wnt1</i> Transcription through Promoting Its Derepression from <i>Six3</i> Corepressor
Data from Metastasis-Associated Protein 1 and Its Short Form Variant Stimulates <i>Wnt1</i> Transcription through Promoting Its Derepression from <i>Six3</i> Corepressor Open
Although Wnt1 downstream signaling components have been well studied and activated in human cancer, the pathways that regulate Wnt1 itself have not been explored in depth. Here, we provide gain-of-function, loss-of function, and mol…